GHRS
GH Research PLC NASDAQ Listed Jun 25, 2021$24.33
-6.28%
vs $25.96
Mkt Cap $1.7B
52w Low $12.04
63.4% of range
52w High $31.44
50d MA $28.35
200d MA $20.62
P/E (TTM)
—
EV/EBITDA
—
P/B
5.3x
Debt/Equity
0.0x
ROE
—
P/FCF
-36.3x
RSI (14)
33.60
ATR (14)
$1.18
Beta
1.00
50d MA
$28.35
200d MA
$20.62
Avg Volume
222.9K
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
28 Baggot Street Lower · Dublin, L2 D02 NX43 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | BMO | -0.29 | -0.23 | +19.6% | 29.13 | +0.7% | +5.2% | -1.2% | -2.4% | -1.5% | +4.0% | — |
| May 14, 2026 | BMO | -0.27 | -0.31 | -14.8% | 21.88 | -1.7% | +1.5% | -3.7% | +1.4% | +1.2% | +2.7% | — |
| May 11, 2026 | BMO | — | — | — | 21.42 | -0.5% | -0.7% | +1.3% | +1.6% | +1.5% | -3.7% | — |
| May 8, 2026 | BMO | — | — | — | 21.01 | -0.2% | +2.0% | -0.7% | +1.3% | +1.6% | +1.5% | — |
| May 7, 2026 | BMO | — | — | — | 22.44 | -0.5% | -6.4% | +2.0% | -0.7% | +1.3% | +1.6% | — |
| Mar 5, 2026 | BMO | -0.29 | -0.23 | +20.7% | 15.17 | +0.6% | +5.0% | +0.3% | -1.4% | -4.0% | +2.6% | — |
| Nov 6, 2025 | BMO | -0.23 | -0.23 | +0.0% | 13.41 | -1.3% | +0.7% | +0.3% | +5.0% | +5.5% | -8.5% | — |
| Aug 7, 2025 | BMO | -0.22 | -0.15 | +31.8% | 12.10 | -0.3% | +2.6% | -4.9% | +2.9% | +3.5% | +1.8% | — |
| May 8, 2025 | BMO | -0.61 | -0.19 | +68.9% | 10.80 | +1.6% | -3.9% | -2.1% | -1.0% | -0.8% | +7.2% | — |
| Feb 27, 2025 | BMO | -0.23 | -0.17 | +26.1% | 10.65 | -2.4% | -4.9% | -9.1% | +2.0% | +10.9% | +1.3% | — |
| Nov 14, 2024 | BMO | -0.25 | -0.23 | +8.0% | 8.97 | +8.5% | +1.3% | +4.2% | +1.5% | +13.9% | -12.1% | — |
| Sep 3, 2024 | BMO | -0.23 | -0.20 | +13.0% | 9.81 | +1.6% | -13.7% | +0.0% | -2.8% | +3.3% | -5.8% | — |
| May 3, 2024 | BMO | -0.22 | -0.15 | +31.8% | 11.68 | +5.3% | +0.1% | +3.3% | -0.7% | +0.0% | +6.8% | — |
| Feb 29, 2024 | BMO | -0.20 | -0.21 | -5.0% | 8.88 | -0.1% | -4.3% | -4.4% | +4.6% | -0.5% | -3.3% | — |
| Nov 9, 2023 | BMO | -0.20 | -0.11 | +45.0% | 7.95 | -1.0% | +3.3% | -8.6% | +1.3% | +3.6% | -7.0% | — |
| Aug 23, 2023 | BMO | -0.25 | -0.15 | +40.0% | 10.50 | +0.7% | -4.0% | -0.4% | +7.9% | +6.6% | -7.4% | — |
| May 11, 2023 | BMO | -0.22 | -0.21 | +4.5% | 10.17 | +6.3% | +4.5% | +2.5% | -3.7% | +5.3% | -3.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27 | Wells Fargo | Initiates | Overweight | $44 | $27.28 | $27.86 | +2.1% | +1.7% | +0.8% | +0.1% | +1.4% | -1.1% |
| Mar 6 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.17 | $15.26 | +0.6% | +5.0% | +0.3% | -1.4% | -4.0% | +2.6% |
| Mar 6 | Needham | Maintains | Buy → Buy | — | $15.17 | $15.26 | +0.6% | +5.0% | +0.3% | -1.4% | -4.0% | +2.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.45 | -2.7% | +7.8% | -4.4% | +4.5% | -5.1% | +5.0% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $16.74 | $16.90 | +1.0% | -0.1% | -0.8% | -2.3% | -0.9% | +1.1% |
| Jan 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.46 | $16.02 | +3.6% | -8.7% | +27.1% | -13.4% | -3.5% | +1.3% |
| Jan 6 | Needham | Maintains | Buy → Buy | — | $15.46 | $16.02 | +3.6% | -8.7% | +27.1% | -13.4% | -3.5% | +1.3% |
| Jan 5 | Needham | Maintains | Buy → Buy | — | $13.24 | $18.82 | +42.1% | +16.8% | -8.7% | +27.1% | -13.4% | -3.5% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.50 | $13.74 | +1.8% | +0.3% | +5.0% | +5.5% | -8.5% | +2.0% |
| Jun 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.68 | $11.76 | +0.7% | +7.4% | -5.2% | +4.3% | +0.3% | -2.0% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $10.80 | $10.97 | +1.6% | -3.9% | -2.1% | -1.0% | -0.8% | +7.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.80 | $10.97 | +1.6% | -3.9% | -2.1% | -1.0% | -0.8% | +7.2% |
| Feb 27 | Stifel | Maintains | Buy → Buy | — | $10.97 | $11.00 | +0.3% | -2.9% | -4.9% | -9.1% | +2.0% | +10.9% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.83 | $8.94 | +1.2% | -0.2% | +7.8% | -0.7% | +2.8% | +9.4% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.57 | $8.29 | -3.3% | -2.6% | -1.9% | +3.3% | +1.7% | +3.3% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $8.72 | -2.9% | -4.6% | -2.6% | -1.9% | +3.3% | +1.7% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.61 | $9.59 | -0.2% | +13.9% | -12.1% | -3.6% | -1.7% | -0.1% |
| Nov 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.09 | $9.05 | -0.4% | +4.2% | +1.5% | +13.9% | -12.1% | -3.6% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.47 | $8.56 | +1.1% | +0.0% | -2.8% | +3.3% | -5.8% | +1.6% |
| Sep 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.81 | $9.97 | +1.6% | -13.7% | +0.0% | -2.8% | +3.3% | -5.8% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.18 | $12.48 | +2.5% | +1.8% | -0.6% | -3.3% | -3.9% | -2.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.69 | $11.75 | +0.5% | +3.3% | -0.7% | +0.0% | +6.8% | +0.5% |
| May 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.68 | $12.30 | +5.3% | +0.1% | +3.3% | -0.7% | +0.0% | +6.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.50 | $8.42 | -0.9% | -4.4% | +4.6% | -0.5% | -3.3% | -0.9% |
| Mar 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.88 | $8.87 | -0.1% | -4.3% | -4.4% | +4.6% | -0.5% | -3.3% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.66 | -1.4% | -1.9% | +3.9% | +3.6% | +0.8% | +3.1% |
| Dec 18 | Stifel | Maintains | Buy → Buy | — | $5.59 | $5.56 | -0.5% | -5.9% | +9.1% | -7.3% | -0.8% | +4.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.50 | $7.65 | +2.0% | +1.3% | +3.6% | -7.0% | -11.7% | -4.3% |
| Jul 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.63 | +1.0% | +0.7% | +0.9% | -2.0% | +0.8% | +2.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.17 | $10.81 | +6.3% | +4.5% | +2.5% | -3.7% | +5.3% | -3.8% |
| May 12 | JMP Securities | Maintains | Outperform → Outperform | — | $10.17 | $10.81 | +6.3% | +4.5% | +2.5% | -3.7% | +5.3% | -3.8% |
| Apr 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $19.42 | $19.50 | +0.4% | -0.5% | +0.5% | -1.8% | -0.1% | -2.4% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management Lp | 13,263,288 | $357M | New | Jun 2026 |
| 2 | Deep Track Capital, Lp | 3,333,334 | $90M | New | Jun 2026 |
| 3 | Rtw Investments, Lp | 5,933,815 | $83M | — | Mar 2026 |
| 4 | Fmr Llc | 5,136,045 | $72M | — | Mar 2026 |
| 5 | Avoro Capital Advisors Llc | 1,800,000 | $25M | — | Mar 2026 |
| 6 | Blackrock, Inc. | 480,287 | $13M | New | Jun 2026 |
| 7 | Millennium Management Llc | 323,399 | $9M | Reduced | Jun 2026 |
| 8 | Ubs Group Ag | 412,416 | $6M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 171,904 | $5M | Added | Jun 2026 |
| 10 | Centerbook Partners Lp | 69,436 | $2M | New | Jun 2026 |
| 11 | Point72 Asset Management, L.p. | 50,882 | $1M | New | Jun 2026 |
| 12 | Morgan Stanley | 102,808 | $1M | Added | Dec 2025 |
| 13 | Marshall Wace, Llp | 91,108 | $1M | Reduced | Mar 2026 |
| 14 | Axxion S.a. | 36,170 | $972K | New | Jun 2026 |
| 15 | Tudor Investment Corp Et Al | 34,278 | $921K | Added | Jun 2026 |
| 16 | D. E. Shaw & Co., Inc. | 25,345 | $681K | New | Jun 2026 |
| 17 | Jane Street Group, Llc | 50,005 | $635K | Added | Dec 2025 |
| 18 | Quadrature Capital Ltd | 21,117 | $568K | New | Jun 2026 |
| 19 | Northern Trust Corp | 32,685 | $460K | — | Mar 2026 |
| 20 | Virtus Investment Advisers, Llc | 15,492 | $416K | Reduced | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 71,267 | $2M | Jun 2026 |
| 2 | iShares MSCI Ireland ETF | 47,400 | $1M | May 2026 |
| 3 | Virtus LifeSci Biotech Clinical Trials ETF | 21,612 | $338K | Jan 2026 |
| 4 | Small Cap Core Fund | 5,998 | $161K | Jun 2026 |
| 5 | Invesco Nasdaq Biotechnology ETF | 3,456 | $51K | Feb 2026 |
| 6 | First Trust IPOX Europe Equity Opportunities ETF | 118 | $2K | Mar 2026 |
Valuation
Market Cap
$1.67B
Enterprise Value
$1.30B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-3.01x
P/B
5.31x
P/S
—
P/FCF
-36.28x
EV/EBITDA
—
Shares Out
61.0M
Financials (TTM)
Revenue
$0
Net Income
-$62.3M
EBITDA
-$61.7M
Free Cash Flow
-$43.7M
Op Cash Flow
-$43.6M
EPS Basic
$-0.79
EPS Diluted
$-1.00
EPS Forward
$-1.46
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$288.2M
Total Liab.
$8.5M
Total Equity
$279.7M
Cash
$280.7M
LT Debt
$0
Book Value/Sh
$4.58
Debt/Equity
0.00x
Current Ratio
34.13
Quick Ratio
34.13
Returns & Growth
ROE
—
ROA
—
ROIC
-21.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-5.3%
Price Returns
2W
-5.8%
1M
-7.6%
3M
+5.5%
6M
+93.9%
12M
+86.6%
Technicals
52W High
$31.44
52W Low
$12.04
50d MA
$28.35
200d MA
$20.62
RSI (14)
33.60
ATR (14)
$1.18
Beta
1.00
Avg Volume
223K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$36.50
High
$40.00
Low
$32.00
Median
$37.00
Data updated apr 25, 2026 11:22am
· Source: financialmodelingprep.com